NCT07830602 Home-based Pulmonary Rehabilitation in Interstitial Lung Disease
| NCT ID | NCT07830602 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Post Graduate Institute of Medical Education and Research, Chandigarh |
| Condition | Interstitial Lung Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2025-11-01 |
| Primary Completion | 2027-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2025-11-01 with a primary completion date of 2027-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pulmonary rehabilitation (PR) is a comprehensive, multidisciplinary intervention incorporating exercise training, education, and behavior change, shown to improve dyspnea, exercise capacity, and health-related quality of life (HRQoL) in ILD patients. However, access to center-based PR is limited in many settings, including ours, due to geographic, logistical, and socioeconomic barriers. Home-based pulmonary rehabilitation (HPR) may offer a scalable, accessible alternative with comparable outcomes to conventional PR. The drawback of HPR is the lack of monitoring, which may be overcome by incorporating a telemonitoring program to improve adherence. Data on the effectiveness of HPR in ILD populations-especially in resource-limited settings-are scarce. Therefore, this study aims to evaluate the impact of a 6-week home-based PR program on HRQoL and exercise capacity in patients with fibrotic ILD in India. The study hypothesis is that participants undergoing HPR will demonstrate clinically meaningful improvements in disease-specific HRQoL and six-minute walk distance compared to those receiving usual care.
Eligibility Criteria
Inclusion Criteria: 1. Age between 18 and 75 years 2. Diagnosis of an ILD by clinician using standard guidelines 3. Having breathlessness graded 1 to 3 on the modified Research Council (mMRC) scale 4. On stable therapy with immunosuppressants or antifibrotics for 3 or more months Exclusion Criteria: 1. Pregnant or lactating women 2. Unwilling to participate in the study 3. Not able to walk or perform upper and lower limb movements 4. Requiring supplemental oxygen
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07830602 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Interstitial Lung Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07830602 currently recruiting?
Yes, NCT07830602 is actively recruiting participants. Contact the research team at sahajal@gmail.com for enrollment information.
Where is the NCT07830602 trial being conducted?
This trial is being conducted at Chandigarh, India.
Who is sponsoring the NCT07830602 clinical trial?
NCT07830602 is sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh. The trial plans to enroll 80 participants.